405 related articles for article (PubMed ID: 33907117)
1. Apatinib combined with S-1 as second-line therapy in advanced gastric cancer.
Qiu ZY; Qin R; Tian GY; Zhang Z; Chen M; He H; Xi Y; Wang Y
Medicine (Baltimore); 2021 Apr; 100(17):e25630. PubMed ID: 33907117
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of apatinib combined with tegafur gimeracil and oteracil potassium in the second-line treatment of advanced gastric cancer.
Chen H; Xue L; Liu L; Li P
J BUON; 2021; 26(3):917-923. PubMed ID: 34268954
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of TAS-114 in combination with S-1 in patients with pretreated advanced gastric cancer (EPOC1604).
Kawazoe A; Takahari D; Keisho C; Nakamura Y; Ikeno T; Wakabayashi M; Nomura S; Tamura H; Fukutani M; Hirano N; Saito Y; Kambe M; Sato A; Shitara K
Gastric Cancer; 2021 Jan; 24(1):190-196. PubMed ID: 32700159
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer].
Feng Q; Zhao JR; Zhang AX; Li SL
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397
[No Abstract] [Full Text] [Related]
5. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer.
Kataoka H; Mori Y; Shimura T; Nishie H; Natsume M; Mochizuki H; Hirata Y; Sobue S; Mizushima T; Sano H; Mizuno Y; Nakamura M; Hirano A; Tsuchida K; Adachi K; Seno K; Kitagawa M; Kawai T; Joh T
Cancer Chemother Pharmacol; 2016 May; 77(5):957-62. PubMed ID: 27002325
[TBL] [Abstract][Full Text] [Related]
6. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
[TBL] [Abstract][Full Text] [Related]
7. Multicenter phase II study of trastuzumab with S-1 plus oxaliplatin for chemotherapy-naïve, HER2-positive advanced gastric cancer.
Takahari D; Chin K; Ishizuka N; Takashima A; Minashi K; Kadowaki S; Nishina T; Nakajima TE; Amagai K; Machida N; Goto M; Taku K; Wakatsuki T; Shoji H; Hironaka S; Boku N; Yamaguchi K
Gastric Cancer; 2019 Nov; 22(6):1238-1246. PubMed ID: 31102009
[TBL] [Abstract][Full Text] [Related]
8. Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients.
Koo DH; Ryu MH; Ryoo BY; Lee SS; Moon JH; Chang HM; Lee JL; Kim TW; Kang YK
Gastric Cancer; 2012 Jul; 15(3):305-12. PubMed ID: 22160244
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of S-1 plus nanoparticle albumin-bound paclitaxel in untreated patients with metastatic gastric cancer.
He MM; Wang F; Jin Y; Yuan SQ; Ren C; Luo HY; Wang ZQ; Qiu MZ; Wang ZX; Zeng ZL; Li YH; Wang FH; Zhang DS; Xu RH
Cancer Sci; 2018 Nov; 109(11):3575-3582. PubMed ID: 30281875
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
12. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
13. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
14. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway.
He MM; Zhang DS; Wang F; Wang ZX; Yuan SQ; Wang ZQ; Luo HY; Ren C; Qiu MZ; Jin Y; Wang DS; Chen DL; Zeng ZL; Li YH; He YY; Hao YT; Guo P; Wang FH; Zeng YX; Xu RH
Cancer Chemother Pharmacol; 2017 Jan; 79(1):69-79. PubMed ID: 27913881
[TBL] [Abstract][Full Text] [Related]
17. S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
Bian NN; Wang YH; Min GT
Int J Surg; 2019 Feb; 62():34-43. PubMed ID: 30641155
[TBL] [Abstract][Full Text] [Related]
18. Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Takahari D; Shimada Y; Takeshita S; Nishitani H; Takashima A; Okita N; Hirashima Y; Kato K; Hamaguchi T; Yamada Y; Shirao K
Gastric Cancer; 2010 Aug; 13(3):186-90. PubMed ID: 20820988
[TBL] [Abstract][Full Text] [Related]
19. Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status.
Chen J; Wang J; Miao Q
Medicine (Baltimore); 2019 Nov; 98(45):e17890. PubMed ID: 31702665
[TBL] [Abstract][Full Text] [Related]
20. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis.
Yang J; Zhou Y; Min K; Yao Q; Xu CN
World J Gastroenterol; 2014 Sep; 20(33):11886-93. PubMed ID: 25206296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]